#USA #New York #class action lawsuit #Faruqi & Faruqi #Regeneron Pharmaceuticals

Upcoming Class Action Lawsuit Against Regeneron Pharmaceuticals

In a significant development for shareholders, Faruqi & Faruqi, LLP, renowned for its expertise in securities law, is urgently reaching out to investors of Regeneron Pharmaceuticals, Inc. This action comes in light of possible misconduct that could have impacted many stakeholders financially. A deadline has been set for March 10, 2025, for those interested in becoming lead plaintiffs in a class action lawsuit against Regeneron.

Background of the Case

The firm is looking into claims suggesting that Regeneron may have misled investors regarding its financial operations, particularly concerning the pricing of its drug, Eylea. It is alleged that the company engaged in practices that inflated sales figures, which subsequently misrepresented its market standing and financial health. The reported claims assert that Regeneron was involved in transactions whereby it allegedly paid credit card fees to distributors under the agreement that they would not charge customers over a certain amount when purchasing Eylea with credit cards.

Legal Allegations

The core of legal accusations includes:
1. Misrepresentation: Regeneron supposedly made misleading statements regarding its pricing strategies and their implications on Eylea's sales performance.
2. False Claims Act Violations: The company allegedly failed to report discounts provided to drug distributors as part of its pricing disclosures, which led to inflated Average Sales Prices (ASP) and disproportionately high Medicare reimbursements.
3. Competitive Disadvantage: By subsidizing treatment costs, Regeneron may have gained an unfair edge over other anti-VEGF treatments available in the market.

These claims stem from actions that ultimately misled investors about the true state of Regeneron's sales figures and business viability, severely impacting stock prices and investor confidence.

Key Dates and Actions

• - Lead Plaintiff Deadline: All potential lead plaintiffs must submit their interest by March 10, 2025. Interested investors must reach out and express their desire to play this critical role in the class action process.
• - Impact on Stock Prices: Following the release of Regeneron's financial results in October 2024, where U.S. net sales for Eylea significantly lagged behind expectations, the company saw its stock tumble. Reports indicated a sharp decline in stock value, dropping as much as 9.2%. This stark reduction highlighted the repercussions of the alleged misrepresentations on investor sentiment and company valuation.

Next Steps for Investors

Investors who have incurred losses exceeding $100,000 from their investments in Regeneron between November 2, 2023, and October 30, 2024, are particularly encouraged to get in touch with Faruqi & Faruqi, LLP. Legal representatives, specifically partner Josh Wilson, are available to discuss the potential claims and guide affected investors through their options.

Conclusion

If you believe you may have been adversely affected by Regeneron's actions and wish to take part in the upcoming class action litigation, do not hesitate to contact the firm for more information. Engaging early can help safeguard your rights and potentially lead to recovery.

For more details, or to initiate discussions, visit Faruqi & Faruqi's website or reach out via phone at 877-247-4292. Stay alert and informed as developments unfold concerning this significant legal matter.